Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Written by Reuben Gregg Brewer for The Motley Fool -> Johnson & Johnson's CEO recently explained that his company isn't going to get caught up in the GLP-1 weight loss drug race. Instead, the company
Nasdaq News — 3 July 2026
Text:
1
0
0
Written by Reuben Gregg Brewer for The Motley Fool -> Johnson & Johnson's CEO recently explained that his company isn't going to get caught up in the
Read Full Story at Nasdaq News → Sources
⚔️ War & Conflict
US strikes Iranian sites in Strait of Hormuz
⚔️ War & Conflict
164 killed as twin quakes flatten Venezuela
⚔️ War & Conflict
Ukraine drones hit Crimea oil depots
⚔️ War & Conflict
Canada's Marsch praises history-making World Cup 'heroes'
⚔️ War & Conflict
Israel orders troops to stay in southern Lebanon
⚔️ War & Conflict
Hezbollah says Israel struck Lebanon hours after truce.
